Communication of Treatment Options for High-Risk NMIBC

Author(s):

Chad A. Reichard, MD ,Karim Chamie, MD, MSHS

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.BCG for treatment of NMIBC

EP: 3.Cystectomy in NMIBC

EP: 4.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 5.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 6.TAR-200 Clinical Development Program in NMIBC

EP: 7.Other Investigational Drug Delivery Systems in NMIBC

EP: 8.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 9.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 10.Use and Sequencing of Novel Treatments in NMIBC

Now Viewing

EP: 11.Communication of Treatment Options for High-Risk NMIBC

EP: 12.Checkpoint Inhibitors for Treatment of NMIBC

EP: 13.Unmet Needs in NMIBC

EP: 14.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 15.Patient Communication and Treatment Adherence in NMIBC

EP: 16.Uptake of New Treatments in Urology Practice

EP: 17.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

How do you communicate various options for NMIBC with patients and healthcare professionals?

Related Videos

Targeted Therapy in mHSPC: Effects of Mutation Absence

Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

Treatment Strategies for Symptomatic Bone Metastases in mHSPC

Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

Adoption of New Treatment Modalities to Treat BPH

Safety data on Black patients from ARANOTE

Current Unmet Needs in ccRCC Diagnosis

Decision-Making in Small Renal Masses